Hypertrophic Cardiomyopathy (HCM) Market Trends
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease and an important cause of sudden death and heart failure symptoms. The current prevalence for HCM is based on echocardiographic population studies in which a substantial proportion of affected subjects have not come to clinical recognition. In addition, most patients with HCM never develop (or recognize) cardiovascular symptoms, experience an adverse disease-related event or are identified with another clinical marker (e.g., abnormal electrocardiogram and family history) which could lead to clinical Recognition.
As per Husser et al. (2018), in Germany Hypertrophic Cardiomyopathy (HCM) prevalence increased gradually with age from 7.4/100,000 persons in 0–9 years old to 298.7/100,000 persons in patients >80 years. In all age categories, men had a numerically higher prevalence than women. As per the article by Marian et al. (2017), the prevalence of Hypertrophic Cardiomyopathy (HCM) has been estimated at 0.16% to 0.29% in the general adult population.
DelveInsight's "Hypertrophic Cardiomyopathy (HCM) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM) Market, historical and forecasted epidemiology, the pipeline insight as well as the Hypertrophic Cardiomyopathy (HCM) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Hypertrophic Cardiomyopathy (HCM) market report also covers emerging drugs, current treatment practices, Hypertrophic Cardiomyopathy (HCM) market shares of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy (HCM) Market Size segmented by seven major markets. The report provides a detailed current Hypertrophic Cardiomyopathy (HCM) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Hypertrophic Cardiomyopathy (HCM) Market Trends Analysis
The Hypertrophic Cardiomyopathy (HCM) market size is expected to increase during the forecast period owing to the increasing prevalent population of Hypertrophic Cardiomyopathy (HCM) in the 7MM.
The Hypertrophic Cardiomyopathy (HCM) market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hypertrophic Cardiomyopathy (HCM) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Hypertrophic Cardiomyopathy (HCM) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hypertrophic Cardiomyopathy (HCM) Epidemiology Forecast
The Hypertrophic Cardiomyopathy (HCM) epidemiology section covers insights about historical and current Hypertrophic Cardiomyopathy (HCM) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Hypertrophic Cardiomyopathy (HCM) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Hypertrophic Cardiomyopathy (HCM) Companies at the global level includes:
MyoKardia
Cytokinetics
Novartis
Celltrion
Palatin Technologies
And many others.
Source: Hypertrophic Cardiomyopathy (HCM) Market Trends